CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
| Project Number | pCODR 10131 |
|---|---|
| Brand Name | Imfinzi |
| Generic Name | Durvalumab |
| Strength | 50 mg |
| Tumour Type | Lung |
| Indication | Non-Small Cell Lung Cancer |
| Funding Request | For the treatment of patients with locally advanced, unresectable non-small cell lung cancer (NSCLC) following curative intent platinum-based chemoradiation therapy, for up to a maximum of 12 months |
| Review Status | Notification to Implement Issued |
| Pre Noc Submission | No |
| NOC Date | May 4, 2018 |
| Manufacturer | AstraZeneca Canada |
| Sponsor | AstraZeneca Canada |
| Submission Date | September 21, 2018 |
| Submission Deemed Complete | October 5, 2018 |
| Submission Type | New Drug |
| Prioritization Requested | |
| Stakeholder Input Deadline ‡ | October 5, 2018 |
| Check-point meeting | November 12, 2018 |
| pERC Meeting | February 21, 2019 |
| Initial Recommendation Issued | March 7, 2019 |
| Feedback Deadline ‡ | March 21, 2019 |
| pERC Reconsideration Meeting | April 18, 2019 |
| Final Recommendation Issued | May 3, 2019 |
| Notification to Implement Issued | May 21, 2019 |
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
